Review

TTK HEALTHCARE LTD.

Ticker : 507747
FV : Rs 10
52-Week H/L: Rs 827.50/456.8

We recommended TTK Healthcare Limited in volume no. 38, issue no. 08 (dated December 13, 2021) when the scrip was trading at Rs 770. On a standalone quarterly front, the company recorded an increase of 29.24 per cent in the net sales & operating income, which stood at Rs 206.36 crore for Q2FY22 as compared to Rs 159.67 crore reported for Q2FY21. The operating profit zoomed robustly by 68.04 per cent, standing at Rs 18.82 crore in Q2FY22 as compared to the operating profit of Rs 11.2 crore recorded in Q2FY21. The company reported a net profit of Rs 12.81 crore in Q2FY22 as compared to Rs 30.81 crore recorded in Q2FY21. Economic growth, rising incidence of chronic diseases, increase in healthcare access, and expected growth in per capita income would drive further expansion of the healthcare segment thereby, giving the company an opportunity to expand in the products it deals with. Hence, we recommend HOLD.